BIOMAT Database Logo BIOMAT Database Logo

Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. 1990

L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Department of Veterinary Microbiology, Faculty of Veterinary Medicine, Biomedical Center, Uppsala, Sweden.

Amino acid sequences inducing neutralizing antibodies to HIV-1 were sought. Murine monoclonal antibodies (MAbs) were characterized by their reactivity with the envelope precursor gp160 or the Escherichia coli recombinant DNA products pB1 and pE3 representing the carboxy- and amino-terminal halves of mature envelope gp120. Fine mapping of the MAb determinants was performed using defined 15-mer synthetic peptides spanning the entire envelope gp120 region of HIV-1. One group of MAbs recognizes epitopes (amino acids 304-323) occurring in a small region with variable and conserved amino acid sequences of gp120. These MAbs mediate neutralization of the HIV-1 strain HTLV-IIIB (HIV-1IIIB) which was used for immunization. Nine out of 11 primary HIV-1 isolates were neutralized well or moderately well. In addition, prominent serological reactivity was noted with peptide sequences of strains of various European or American origins, but not with two HIV-1 strains of African origin. The cross-reactivity contrasts with previously described type-specific reactions to other sequences of this region. The reactivity to the short conserved site GPGR with its flanking amino acids may explain the broad sequence cross-reactivity seen with our neutralizing MAbs. Two other MAbs recognize conserved epitopes (amino acids 79-103) situated in the amino-terminal region of gp120. These MAbs did not neutralize HIV-1IIIB.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010449 Peptide Mapping Analysis of PEPTIDES that are generated from the digestion or fragmentation of a protein or mixture of PROTEINS, by ELECTROPHORESIS; CHROMATOGRAPHY; or MASS SPECTROMETRY. The resulting peptide fingerprints are analyzed for a variety of purposes including the identification of the proteins in a sample, GENETIC POLYMORPHISMS, patterns of gene expression, and patterns diagnostic for diseases. Fingerprints, Peptide,Peptide Fingerprinting,Protein Fingerprinting,Fingerprints, Protein,Fingerprint, Peptide,Fingerprint, Protein,Fingerprinting, Peptide,Fingerprinting, Protein,Mapping, Peptide,Peptide Fingerprint,Peptide Fingerprints,Protein Fingerprint,Protein Fingerprints
D011498 Protein Precursors Precursors, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
May 2002, Proceedings of the National Academy of Sciences of the United States of America,
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
GP120: target for neutralizing HIV-1 antibodies.
January 2006, Annual review of immunology,
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies.
December 2009, Viruses,
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.
November 2011, Journal of virology,
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Monoclonal antibodies to HIV-1 gp120: a request.
July 1993, AIDS research and human retroviruses,
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Sequential antigen panning for selection of broadly cross-reactive HIV-1-neutralizing human monoclonal antibodies.
January 2009, Methods in molecular biology (Clifton, N.J.),
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Human Anti-HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1.
February 2019, Journal of immunology (Baltimore, Md. : 1950),
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
[Localization of the HIV-1 gp120 conformational epitope recognized by virus neutralizing monoclonal antibodies 2G12].
January 2002, Molekuliarnaia biologiia,
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
January 1993, Journal of immunology (Baltimore, Md. : 1950),
L Akerblom, and J Hinkula, and P A Broliden, and B Mäkitalo, and T Fridberger, and J Rosen, and M Villacres-Eriksson, and B Morein, and B Wahren
Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies.
June 2007, Journal of molecular biology,
Copied contents to your clipboard!